DaganNBardaNKeptenE, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412-1423.
4.
DiFioriJPGreenGMeeuwisseWPutukianMSolomonGSSillsA. Return to sport for North American professional sport leagues in the context of COVID-19. Br J Sports Med. 2021;55:417-421.
5.
EichhornCBiereLSchnellF, et al. Myocarditis in athletes is a challenge: diagnosis, risk stratification, and uncertainties. JACC Cardiovasc Imaging. 2020;13:494-507.
6.
HarrisMD. Infectious disease in athletes. Curr Sports Med Rep. 2011;10:84-89.
7.
JaworskiCARygielV.Acute illness in the athlete. Clin Sports Med. 2019;38:577-595.
8.
MartinezMWTuckerAMBloomOJ, et al. Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening. JAMA Cardiol. 2021;6:745-752.
9.
MoulsonNPetekBJDreznerJA, et al. SARS-CoV-2 cardiac involvement in young competitive athletes. Circulation. 2021;144:256-266.
10.
PhelanDKimJHChungEH. A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) Infection. JAMA Cardiol. 2020;5:1085-1086.
11.
RajpalSTongMSBorchersJ, et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2021;6:116-118.
ShahABNabhanDChapmanR, et al. Resumption of sport at the United States Olympic and Paralympic training facilities during the COVID-19 pandemic. Sports Health. 2021;13:359-363.
WolterNJassatWWalazaS, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399:437-446.